PL2517700T3 - Farmaceutyczne dopuszczalne kokryształy n-[2-(7-metoksy-1-naftylo]acetamidu i sposoby ich wytwarzania - Google Patents

Farmaceutyczne dopuszczalne kokryształy n-[2-(7-metoksy-1-naftylo]acetamidu i sposoby ich wytwarzania

Info

Publication number
PL2517700T3
PL2517700T3 PL11075073T PL11075073T PL2517700T3 PL 2517700 T3 PL2517700 T3 PL 2517700T3 PL 11075073 T PL11075073 T PL 11075073T PL 11075073 T PL11075073 T PL 11075073T PL 2517700 T3 PL2517700 T3 PL 2517700T3
Authority
PL
Poland
Prior art keywords
acetamide
naphthyl
methoxy
preparation
methods
Prior art date
Application number
PL11075073T
Other languages
English (en)
Inventor
Gary James Miller
Ludek Ridvan
Jindrich Richter
Ondrej Dammer
Tomas Chvojka
Tomas Pekarek
Winfried Heyse
Norbert Nagel
Original Assignee
Zentiva Ks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva Ks filed Critical Zentiva Ks
Publication of PL2517700T3 publication Critical patent/PL2517700T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11075073T 2011-04-28 2011-04-28 Farmaceutyczne dopuszczalne kokryształy n-[2-(7-metoksy-1-naftylo]acetamidu i sposoby ich wytwarzania PL2517700T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11075073.4A EP2517700B1 (en) 2011-04-28 2011-04-28 Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation

Publications (1)

Publication Number Publication Date
PL2517700T3 true PL2517700T3 (pl) 2013-12-31

Family

ID=44519907

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11075073T PL2517700T3 (pl) 2011-04-28 2011-04-28 Farmaceutyczne dopuszczalne kokryształy n-[2-(7-metoksy-1-naftylo]acetamidu i sposoby ich wytwarzania

Country Status (16)

Country Link
US (1) US8927771B2 (pl)
EP (1) EP2517700B1 (pl)
JP (1) JP5770928B2 (pl)
KR (1) KR20140008370A (pl)
CN (1) CN103501777B (pl)
BR (1) BR112013023471A2 (pl)
EA (1) EA024422B1 (pl)
ES (1) ES2429348T3 (pl)
IL (1) IL228916A (pl)
MX (1) MX342807B (pl)
PL (1) PL2517700T3 (pl)
PT (1) PT2517700E (pl)
RS (1) RS52982B (pl)
UA (1) UA111844C2 (pl)
WO (1) WO2012146371A1 (pl)
ZA (1) ZA201307688B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012000132A1 (en) 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
EP2551257A1 (en) * 2011-07-28 2013-01-30 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of agomelatine with co-crystal-formers
KR20150020191A (ko) * 2012-05-14 2015-02-25 상하이 라이트핸드 팜테크 주식회사 아고멜라틴 산기 복합체와 그의 제조방법 및 용도
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
ES2590908T3 (es) 2012-12-17 2016-11-24 Dr. Reddy's Laboratories Ltd. Cocristal de agomelatina con ácido fosfórico
PT2810656T (pt) 2013-06-06 2017-11-13 Zentiva As Formulações de agomelatina compreendendo agomelatina na forma de cocristais
EP2810647A1 (en) * 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
FR3012142B1 (fr) * 2013-10-17 2016-07-15 Servier Lab Nouveaux complexes d'agomelatine et d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2015013865A1 (en) * 2013-07-29 2015-02-05 Les Laboratoires Servier Agomelatine sulfonic acids complexes and preparation thereof
HUE049928T2 (hu) * 2013-07-29 2020-11-30 Servier Lab Agomelatin és szulfonsavak komplexei, eljárás elõállításukra, és ezeket tartalmazó gyógyszerészeti készítmények
WO2015013903A1 (en) * 2013-07-31 2015-02-05 Les Laboratoires Servier NEW AGOMELATINE p-TOLUENESULFONIC ACID CO-CRYSTAL FORMS AND PREPARATION THEREOF
CN105473551B (zh) * 2013-07-31 2019-01-11 法国施维雅药厂 阿戈美拉汀和对甲苯磺酸的共晶的新形式、其制备方法和包含其的药物组合物
LT3036218T (lt) * 2013-07-31 2019-05-27 Les Laboratoires Servier Agomelatino ir p-toluensulfonrūgšties monohidrato bendri kristalai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos
KR101404836B1 (ko) 2014-03-21 2014-06-09 순천향대학교 산학협력단 아고멜라틴의 공결정 및 그의 제조방법
KR101470794B1 (ko) * 2014-06-30 2014-12-08 순천향대학교 산학협력단 아고멜라틴 공결정의 제조 방법 및 이를 포함하는 조성물
EP3075724B1 (en) 2015-03-31 2023-07-12 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Solid form of agomelatine
WO2017115284A1 (en) * 2015-12-28 2017-07-06 Leiutis Pharmaceuticals Pvt, Ltd. Novel co-crystal forms of agomelatine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514733A1 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
WO2008035177A2 (en) * 2006-09-18 2008-03-27 Copharm Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN102106806B (zh) * 2009-12-29 2013-04-17 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2012046253A2 (en) 2010-10-08 2012-04-12 Msn Laboratories Limited Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
KR20140008370A (ko) 2014-01-21
EP2517700B1 (en) 2013-07-17
US8927771B2 (en) 2015-01-06
IL228916A0 (en) 2013-12-31
EP2517700A1 (en) 2012-10-31
UA111844C2 (uk) 2016-06-24
MX2013012103A (es) 2014-01-24
RS52982B (en) 2014-02-28
JP2014522388A (ja) 2014-09-04
EA024422B1 (ru) 2016-09-30
IL228916A (en) 2016-05-31
ZA201307688B (en) 2015-04-29
EA201391574A1 (ru) 2014-04-30
CN103501777A (zh) 2014-01-08
JP5770928B2 (ja) 2015-08-26
MX342807B (es) 2016-10-13
ES2429348T3 (es) 2013-11-14
PT2517700E (pt) 2013-10-14
BR112013023471A2 (pt) 2016-12-13
US20140051887A1 (en) 2014-02-20
CN103501777B (zh) 2015-08-19
WO2012146371A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
PL2517700T3 (pl) Farmaceutyczne dopuszczalne kokryształy n-[2-(7-metoksy-1-naftylo]acetamidu i sposoby ich wytwarzania
EP2705023A4 (en) PROCESSES FOR THE PREPARATION OF N- [2- (7-METHOXY-1-NAPHTHYLLELYHYL) ACETAMIDE
HK1199820A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
EP2573070A4 (en) CRYSTAL FORM OF (S) -4-HYDROXY-2-OXO-1-PYRROLIDINACETAMIDE, METHOD OF MANUFACTURE AND USE THEREOF
SI2704703T1 (sl) Transdermalni sestavki ibuprofena in postopki za njihovo uporabo
EP2691120A4 (en) THERANOSTIC IMAGING AGENTS AND METHODS OF USE
IL237655A0 (en) An improved process for the preparation of vilantrol and intermediates
EP2526099A4 (en) IMPROVED METHOD FOR THE MANUFACTURE OF AMID INTERMEDIATE PRODUCTS AND ITS APPLICATION
IL261232A (en) A pharmaceutical formulation for reducing urinary frequency and a method for its use
HK1193087A1 (en) New crystal form vii of agomelatine, preparation method and use thereof and pharmaceutical composition containing same vii
IL223180A0 (en) Agomelatine intermediates and preparation method thereof
RS54753B9 (sr) Postupak i intermedijerni proizvodi za sintezu agomelatina
PL2546066T5 (pl) Materiał rejestrujący wrażliwy na ciśnienie i jego sposób otrzymywania
HUP1100238A2 (en) Novel process for the preparation of pharmaceutically active ingredient and the intermediates arose during the process
HUP1100239A2 (en) Novel process for the preparation of pharmaceutically active ingredient and the intermediates arose during the process
IT1397920B1 (it) Forma cristallina di fesoterodina fumarato e procedimento per la sua preparazione